Fractyl Health cuts 45% of workforce to focus on Revita
Fractyl Health will lay off about 45 of roughly 100 Burlington employees, end its Rejuva gene-therapy program and focus on Revita, an FDA approval candidate for weight maintenance.

By Priya Raman
Fractyl Health will lay off about 45 of roughly 100 employees in Burlington after announcing a 45% workforce reduction Thursday.
Fractyl currently employs about 100 people, according to Boston Business Journal. The company announced the reduction as it focused all efforts on one product and discontinued development of its Rejuva gene therapy program. Both figures are approximate, and the report provides no exact layoff roster.
The 45% reduction is a company-specific figure, not a measure of wider biotechnology layoffs. The report provides no national layoff benchmark or role-level breakdown. For job seekers, that distinction matters: one company’s 45% contraction cannot stand in for an industry rate, and the announcement offers no comparison with earlier cuts at similar-sized biotechnology employers.
The retained product is Revita. Fractyl describes Revita as a treatment intended to help patients maintain weight after using GLP-1 obesity drugs. The company is pursuing market approval from the U.S. Food and Drug Administration. Its stated focus includes treatments for type 2 diabetes and obesity.
“While these decisions are difficult, particularly those impacting our colleagues, we believe this focused strategy will position Fractyl to operate more efficiently and advance Revita toward its clinical and commercial potential,” said co-founder and CEO Harith Rajagopalan in a news release.
Leadership will also change. Co-founder, President and Chief Product Officer Jay Caplan will retire on Oct. 30 and remain as a senior adviser to the company’s leadership team. Caplan’s move leaves the executive structure unsettled because the announcement names no successor to his president or chief product officer roles.
“Jay has been instrumental in building the Company. We are deeply grateful for his dedication and lasting contributions, as well as those of all our colleagues affected by this transition,” Rajagopalan said.
What does this change for workers and job applicants?
For the approximately 45 affected employees, the change is immediate: Fractyl expects to complete the reduction by next month, while the announcement provides no severance terms, role-by-role list or hiring plan. Employees who remain will work in a company about 45% smaller, with their work more tightly tied to Revita’s regulatory and commercial path.
For applicants, the distinction is narrower but clearer. A role tied to Revita sits inside the company’s retained priority, while a role tied to Rejuva sits inside a program whose development Fractyl has ended. Because the announcement identifies no affected functions or titles, candidates cannot infer which biotech specialties remain open. Fractyl has also disclosed no hiring plan or vacancies tied to potential expansion.
The layoff completion date and Caplan’s Oct. 30 retirement provide the only near-term personnel deadlines disclosed in the report. Fractyl did not announce an FDA decision date for Revita or a separate Rejuva wind-down schedule.
With layoffs due to finish by next month, Revita’s path to FDA approval will test whether the 45% reduction delivers the operating efficiency Rajagopalan described; no decision timeline was announced.
Source: Google News: Layoffs
More from Priya Raman
Show full bio
Market editor covering people, launches and day-to-day practice in Job market data and labor economics at Path & Pay.
606 articles
Go deeper
- Novo Nordisk cuts 108 jobs at New Jersey US headquarters
- Novo Nordisk Workforce Shrinks by 13,000, BioSpace Tracker Shows
- BioMarin Cuts 117 California Roles in Footprint Consolidation
- 64% of Biopharma Workers Say They've Been Laid Off in Five Years
- BioMarin to Cut 119 Jobs in Novato Manufacturing Consolidation